
## MarÃ-a Rosa LÃ<sup>3</sup>pez-Huertas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4398617/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nature Reviews Microbiology, 2009, 7, 798-812.	28.6	235
2	Modifications in the human Tâ€cell proteome induced by intracellular HIV-1 Tat protein expression. Proteomics, 2006, 6, S63-S73.	2.2	66
3	Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells. Biochemical Pharmacology, 2016, 106, 30-45.	4.4	50
4	The Presence of HIV-1 Tat Protein Second Exon Delays Fas Protein-mediated Apoptosis in CD4+ T Lymphocytes. Journal of Biological Chemistry, 2013, 288, 7626-7644.	3.4	47
5	Two RT-PCR based assays to detect human metapneumovirus in nasopharyngeal aspirates. Journal of Virological Methods, 2005, 129, 1-7.	2.1	46
6	Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers. Frontiers in Immunology, 2022, 13, 848886.	4.8	45
7	The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1. Scientific Reports, 2017, 7, 2385.	3.3	38
8	Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 <sup>+</sup> T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy. Journal of Virology, 2018, 92, .	3.4	36
9	Basal shuttle of NF-κB/lκBα in resting T lymphocytes regulates HIV-1 LTR dependent expression. Retrovirology, 2007, 4, 56.	2.0	34
10	Application of proteomics technology for analyzing the interactions between host cells and intracellular infectious agents. Proteomics, 2008, 8, 852-873.	2.2	31
11	Protein Kinase CÎ, Is a Specific Target for Inhibition of the HIV Type 1 Replication in CD4+ T Lymphocytes*. Journal of Biological Chemistry, 2011, 286, 27363-27377.	3.4	29
12	Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Frontiers in Immunology, 2021, 12, 665329.	4.8	26
13	Caspase-3-mediated cleavage of p65/RelA results in a carboxy-terminal fragment that inhibits lκBα and enhances HIV-1 replication in human T lymphocytes. Retrovirology, 2008, 5, 109.	2.0	25
14	Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU. Frontiers in Immunology, 2021, 12, 742631.	4.8	23
15	Analysis of protein kinase C theta inhibitors for the control of HIV-1 replication in human CD4+ T cells reveals an effect on retrotranscription in addition to viral transcription. Biochemical Pharmacology, 2015, 94, 241-256.	4.4	22
16	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	4.7	22
17	Changes in the cellular microRNA profile by the intracellular expression of HIV-1 Tat regulator: A potential mechanism for resistance to apoptosis and impaired proliferation in HIV-1 infected CD4+ T cells. PLoS ONE, 2017, 12, e0185677.	2.5	21
18	Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D. Biomedicine and Pharmacotherapy, 2022, 150, 112965.	5.6	20

#	Article	IF	CITATIONS
19	Oligonucleotide microarray design for detection and serotyping of human respiratory adenoviruses by using a virtual amplicon retrieval software. Journal of Virological Methods, 2007, 145, 127-136.	2.1	16
20	Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers. Emerging Microbes and Infections, 2021, 10, 493-496.	6.5	15
21	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. Biochemical Pharmacology, 2018, 156, 248-264.	4.4	14
22	Dual role of host cell factors in HIV-1 replication: restriction and enhancement of the viral cycle. AIDS Reviews, 2010, 12, 103-12.	1.0	14
23	Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Journal of Clinical Medicine, 2021, 10, 42.	2.4	13
24	Transcription elongation regulator 1 (TCERG1) regulates competent RNA polymerase II-mediated elongation of HIV-1 transcription and facilitates efficient viral replication. Retrovirology, 2013, 10, 124.	2.0	12
25	PKCÎ, and HIV-1 Transcriptional Regulator Tat Co-exist at the LTR Promoter in CD4+ T Cells. Frontiers in Immunology, 2016, 7, 69.	4.8	9
26	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. Biochemical Pharmacology, 2020, 182, 114203.	4.4	9
27	Synthesis of recombinant human parainfluenza virus 1 and 3 nucleocapsid proteins in yeast Saccharomyces cerevisiae. Virus Research, 2008, 133, 178-186.	2.2	8
28	Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochemical Pharmacology, 2021, 192, 114666.	4.4	8
29	Hepatitis C Virus Influences HIV-1 Viral Splicing in Coinfected Patients. Journal of Clinical Medicine, 2020, 9, 2091.	2.4	3
30	Identification of Immunological Parameters Related to Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission. Blood, 2019, 134, 191-191.	1.4	2
31	Molecular mechanisms involved in HIV latency and implications for HIV treatment and eradication. Retrovirology, 2010, 7, .	2.0	1
32	Transcriptomic Evidence of the Immune Response Activation in Individuals With Limb Girdle Muscular Dystrophy Dominant 2 (LGMDD2) Contributes to Resistance to HIV-1 Infection. Frontiers in Cell and Developmental Biology, 2022, 10, .	3.7	1
33	Modifications in host cell structure and functions mediated by Tat intracellular expression are greatly dependent on the second exon. Retrovirology, 2009, 6, .	2.0	0
34	Characterization of the Early Humoral and Cellular Response Developed in Oncohematological Patients Post-Vaccination with One Dose Against COVID-19. Blood, 2021, 138, 195-195.	1.4	0
35	Characterization of the Humoral and Cellular Immune Response Against the Natural Infection By Sars-Cov-2 in Oncohematological Patients with Post-COVID19 Autologous Transplantation. Blood, 2021, 138, 5040-5040.	1.4	0